or
Remember me
Back
HERZLIYA, Israel and CALGARY, AB, Jan. 29, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that its subsidiary, BI Sky Global (BI), successfully completed the Human Repeated Insult Patch Test (HRIPT) for Sensitization and Irritation Testing, ensuring the safety of its cosmetic products. HRIPT is the personal care industry's standard safety test for cosmetic, OTC drug, and topical medical devices.
In addition, the Company announced that it has surpassed the important sales milestone of an average of 5,000 units per day in 2024. This achievement is particularly significant as the typical minimum production quantity for most cosmetic products is 5,000 units in total, while BI Sky Global sells this amount daily. This significant sales volume far exceeds the requirements for annual production agreements with key third-party manufacturing companies.
Receive investor kits and email updates from Stockhouse and directly from these companies.
